Morgan Stanley (NY:MS)

190.31 +2.30 (+1.22%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Morgan Stanley

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stocks making big moves yesterday: Corning, Baldwin Insurance Group, Gartner, Jabil, and Accenture

September 15, 2026

Check out the companies making headlines yesterday: Corning (NYSE:GLW): Glass and electronic component manufacturer Corning (NYSE:GLW) fell by 12.7% on Monda...

Via StockStory

Topics Artificial Intelligence

Wall Street Sells the AI-Pause Weekend as Brent Punches Through $106 and the Ten-Year Cracks 5% for the First Time Since 2023 ↗

September 15, 2026

Via Chartmill

Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near ↗

September 15, 2026

Sarepta Therapeutics (NASDAQ:SRPT) outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic...

Via MarketBeat

Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience ↗

September 15, 2026

Biogen (NASDAQ:BIIB) is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley...

Via MarketBeat

Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss ↗

September 14, 2026

Viking Therapeutics (NASDAQ:VKTX) said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after 13...

Via MarketBeat

Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum ↗

September 14, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global...

Via MarketBeat

Topics Intellectual Property

Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform ↗

September 14, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded...

Via MarketBeat

Topics World Trade

CRISPR Therapeutics Eyes CASGEVY Growth, Year-End Pipeline Catalysts ↗

September 14, 2026

CRISPR Therapeutics (NASDAQ:CRSP) CEO Sam Kulkarni outlined the company’s commercial and clinical priorities during a Morgan Stanley discussion, highlighting continued adoption of CASGEVY and expected...

Via MarketBeat

Topics Intellectual Property

Merck CEO Sees Pipeline Upside as Launches, Animal Health Drive Transformation ↗

September 14, 2026

Merck & Co., Inc. (NYSE:MRK) Chairman and CEO Rob Davis said the company’s “transformation is underway,” citing progress across product launches, clinical data readouts, business development and its...

Via MarketBeat

Eli Lilly Eyes Obesity Access Expansion With Zepbound, Foundayo and Pipeline Bets ↗

September 14, 2026

Eli Lilly and Company (NYSE:LLY) is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing...

Via MarketBeat

Why Accenture (ACN) Stock Is Up Today

September 14, 2026

What Happened? Shares of global professional services company Accenture (NYSE:ACN) jumped 5.2% in the afternoon session after Morgan Stanley raised its price...

Via StockStory

Topics Artificial Intelligence

Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition ↗

September 14, 2026

Johnson & Johnson (NYSE:JNJ) executives said the company remains on track to grow through biosimilar competition for STELARA and expects its portfolio of medicines, medical devices and pipeline...

Via MarketBeat

Topics ETFs Economy

Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center Stage ↗

September 14, 2026

Pfizer (NYSE:PFE) Chairman and Chief Executive Officer Albert Bourla said the drugmaker has addressed several major headwinds that weighed on investor attention, including policy uncertainty, declining...

Via MarketBeat

Topics Intellectual Property World Trade

Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types ↗

September 14, 2026

Moderna (NASDAQ:MRNA) President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma...

Via MarketBeat

Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars ↗

September 14, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics...

Via MarketBeat

McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal ↗

September 14, 2026

McKesson (NYSE:MCK) executives said the company’s first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology &...

Via MarketBeat

Morgan Stanley Inclusive & Sustainable Ventures Announces 2026 Global Cohort of Innovators

September 14, 2026

From Morgan Stanley

Via Business Wire

Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead ↗

September 14, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company’s...

Via MarketBeat

Billionaire David Einhorn Says SpaceX Is Making History, but Not in a Good Way ↗

September 14, 2026

SpaceX will need substantial capital to pursue its various business ventures.

Via The Motley Fool

Topics Bonds Initial Public Offering

Joby Aviation Could Deliver 10x Returns for Patient Investors ↗

September 12, 2026

On paper, a tenfold gain isn't far-fetched, but can Joby deliver it?

Via The Motley Fool

Topics Economy

Here's How Much $100 Invested In Morgan Stanley 10 Years Ago Would Be Worth Today ↗

September 11, 2026

Morgan Stanley (NYSE:MS) has outperformed the market over the past 10 years by 7.4% on an annualized basis producing an average annual return of 20.97%. Currently, Morgan Stanley has a market...

Via Benzinga

2 Stocks Cathie Wood Is Snapping Up at a Discount Right Now ↗

September 11, 2026

Several Ark funds recently bought the dip in Meta and Rocket Lab.

Via The Motley Fool

Topics Artificial Intelligence ETFs Earnings

Why Under Armour (UAA) Stock Is Trading Up Today

September 11, 2026

What Happened? Shares of athletic apparel company Under Armour (NYSE:UAA) jumped 1.9% in the afternoon session after Morgan Stanley resumed coverage of the s...

Via StockStory

Morgan Stanley Sees $80 Billion Tesla Semi Opportunity as Diesel Hits Record $6.06 ↗

September 11, 2026

Morgan Stanley says Tesla Semi could add $80B in value as record $6.06 diesel strengthens the case for autonomous electric trucking.

Via Benzinga

Topics Energy

Tesla Semi Gets Boost From $6 Diesel; Morgan Stanley Says Earnings Potential 'Underappreciated' ↗

September 11, 2026

$6 diesel will help the Tesla Semi gain momentum, Morgan Stanley, which sees the big rig as an "underappreciated" earnings driver long term.

Via Investor's Business Daily

Topics Energy

BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in Morgan Stanley Global Healthcare Conference

September 10, 2026

Via Investor Brand Network

3 Overlooked Reasons Now Might Be the Time to Buy Ford Stock ↗

September 09, 2026

Ford offers investors a unique blend of legacy automotive stability and heavy investment in future ambitions. Here are three overlooked reasons Ford should intrigue investors.

Via The Motley Fool

Topics Electric Vehicles

As Anthropic's IPO Looms, This Small Financial Powerhouse Just Got Its First Underwriting Job ↗

September 09, 2026

This adds another market to its broad financial ecosystem.

Via The Motley Fool

Topics Artificial Intelligence Earnings Initial Public Offering

Stock Market Today, Sept. 9: Meta Surges Over 6.5% on Muse AI Agent Launch ↗

September 09, 2026

Today, Sept. 9, 2026, investors are watching whether the autonomous agent can unlock a new revenue stream for the social platform.

Via The Motley Fool

Topics Artificial Intelligence Stocks

Brent Tops $100 as Morgan Stanley Warns Oil, Rates Are ‘Main Risks’ to Stocks ↗

September 09, 2026

Brent topped $100 as Morgan Stanley warned oil and rates are the main risks to stocks, while traders bet fighting eases this month.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.